Fluvastatin-Pretreated Donor Cells Attenuated Murine aGVHD by Balancing Effector T Cell Distribution and Function under the Regulation of KLF2

Figure 1

The expression of KLF2 was increased after statin treatment in vitro and in vivo. (a) Bone marrow cells of C57BL/6 mice were cultured with Fluvastatin (200 μmol/l) or Simvastatin (200 μmol/l) or equal volume of PBS for 18 hours and stimulated with or without plate-bound anti-CD3 plus soluble-CD28 in vitro for additional 6 hours. Then, cells were collected for detection of KLF2 expression by Western blot. Experiments were repeated twice, and the culture was set up in triplicate. Cells in statin-treated groups were compared to those in buffer controls, and statistical analysis was done. (b) C57BL/6 mice were daily i.p. injeced of Fluvastatin or PBS () for 7 consecutive days and withdraw drug administration, and then, on days 7, 10, and 17, mice were killed to collect samples. KLF2 mRNA and protein levels (c) in bone marrow cells and spleen cells which were stimulated with or without anti-CD3 and anti-CD28 were analyzed by qRT-PCR and Western blot, respectively. Two independent experiments were repeated. Cells collected at each time point in Fluvastatin groups were compared to those in the buffer controls. , , n.s .

(a)

(b)

(c)